Evidence map›Paper›PMID 38821719›Full record

ArticleJournal for immunotherapy of cancer2024

An innovative single-cell approach for phenotyping and functional genotyping of CAR NK cells.

Matthew Ryan Sullivan, Michael Finocchiaro, Yichao Yang, Judene Thomas, Alaa Ali, Isabel Kaplan, Yasmin Abdulhamid, Eden Bobilev, Michal Sheffer, Rizwan Romee and 1 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matthew Ryan Sullivan *Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA.
Michael Finocchiaro *Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA.
Yichao YangDepartment of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA.
Judene ThomasDepartment of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA.
Alaa AliDana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Isabel KaplanDana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Yasmin AbdulhamidDana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Eden BobilevDana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Michal ShefferDana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Rizwan RomeeDana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA taniakonrylab@gmail.com Rizwan_Romee@DFCI.HARVARD.EDU.ORCID http://orcid.org/0000-0001-9077-4736
Tania KonryDepartment of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA taniakonrylab@gmail.com Rizwan_Romee@DFCI.HARVARD.EDU.ORCID http://orcid.org/0000-0001-8234-631X

Funding

Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platformR33CA223908 · NCI · NORTHEASTERN UNIVERSITY · PI EVENS, ANDREW M, HUANG, TONY JUN · 2018 to 2020
$1.2M
An integrated acoustofluidic droplet-sorting platform for classification of lymphocyte activity and functional phenotyping at single cell levelR01GM127714 · NIGMS · NORTHEASTERN UNIVERSITY · PI KONRY, TANIA TALI · 2018 to 2021
$1.2M
NCI NIH HHS R33 CA223908NIGMS NIH HHS R01 GM127714
6 · The paper itself

Abstract

backgroundTo accelerate the translation of novel immunotherapeutic treatment approaches, the development of analytic methods to assess their efficacy at early in vitro stages is necessary. Using a droplet-based microfluidic platform, we have established a method for multiparameter quantifiable phenotypic and genomic observations of immunotherapies. Chimeric antigen receptor (CAR) natural killer (NK) cells are of increased interest in the current immunotherapy landscape and thus provide an optimal model for evaluating our novel methodology.

methodsFor this approach, NK cells transduced with a CD19 CAR were compared with non-transduced NK cells in their ability to kill a lymphoma cell line. Using our microfluidic platform, we were able to quantify the increase in cytotoxicity and synaptic contact formation of CAR NK cells over non-transduced NK cells. We then optimized our droplet sorter and successfully used it to separate NK cells based on target cell killing to perform transcriptomic analyses.

resultsOur data revealed expected improvement in cytotoxicity with the CD19 CAR but more importantly, provided unique insights into the factors involved in the cytotoxic mechanisms of CAR NK cells. This demonstrates a novel, improved system for accelerating the pre-clinical screening of future immunotherapy treatments.

conclusionsThis study provides a new potential approach for enhanced early screening of immunotherapies to improve their development, with a highly relevant cell model to demonstrate. Additionally, our validation studies provided some potential insights into transcriptomic determinants influencing CAR NK cytotoxicity.

Indexed as

Killer Cells, NaturalReceptors, Chimeric AntigenSingle-Cell AnalysisCell Line, TumorCytotoxicity, ImmunologicGenotypeHumansImmunotherapy, AdoptivePhenotypeReceptors, Chimeric Antigenchimeric antigen receptor - CARlymphomanatural killer - NK

Identifiers

PMID38821719
PMCPMC11149162

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.